Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 16 GBX Market Closed
Market Cap: 65.9m GBX
Have any thoughts about
Creo Medical Group PLC?
Write Note

Creo Medical Group PLC
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Creo Medical Group PLC
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Creo Medical Group PLC
LSE:CREO
PP&E Net
ÂŁ8.5m
CAGR 3-Years
39%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
PP&E Net
$1.4B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
PP&E Net
$220.9m
CAGR 3-Years
4%
CAGR 5-Years
-1%
CAGR 10-Years
18%
EKF Diagnostics Holdings PLC
LSE:EKF
PP&E Net
ÂŁ24.9m
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
9%
Angle PLC
LSE:AGL
PP&E Net
ÂŁ6.7m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
PP&E Net
$399.6k
CAGR 3-Years
1%
CAGR 5-Years
69%
CAGR 10-Years
N/A
No Stocks Found

Creo Medical Group PLC
Glance View

Market Cap
65.9m GBX
Industry
Health Care

Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.

CREO Intrinsic Value
25.93 GBX
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Creo Medical Group PLC's PP&E Net?
PP&E Net
8.5m GBP

Based on the financial report for Jun 30, 2024, Creo Medical Group PLC's PP&E Net amounts to 8.5m GBP.

What is Creo Medical Group PLC's PP&E Net growth rate?
PP&E Net CAGR 5Y
49%

Over the last year, the PP&E Net growth was -12%. The average annual PP&E Net growth rates for Creo Medical Group PLC have been 39% over the past three years , 49% over the past five years .

Back to Top